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Abstract
Background: Quite a few randomized controlled trials (RCTs) investigating the efficacy of platelet-rich plasma (PRP)
for treatment of knee osteoarthritis (OA) have been recently published. Therefore, an updated systematic review
was performed to evaluate the temporal effect of PRP on knee pain and physical function.
Methods: Pubmed, Embase, Cochrane library, and Scopus were searched for human RCTs comparing the efficacy
and/or safety of PRP infiltration with other intra-articular injections. A descriptive summary and quality assessment
were performed for all the studies finally included for analysis. For studies reporting outcomes concerning Western
Ontario and McMaster Universities Arthritis Index (WOMAC) or adverse events, a random-effects model was used for
data synthesis.
Results: Fourteen RCTs comprising 1423 participants were included. The control included saline placebo, HA, ozone,
and corticosteroids. The follow-up ranged from 12 weeks to 12 months. Risk of bias assessment showed that 4 studies
were considered as moderate risk of bias and 10 as high risk of bias. Compared with control, PRP injections significantly
reduced WOMAC pain subscores at 3, 6, and 12 months follow-up (p = 0.02, 0.004, <0.001, respectively); PRP
significantly improved WOMAC physical function subscores at 3, 6, and 12 months (p = 0.002, 0.01, <0.001,
respectively); PRP also significantly improved total WOMAC scores at 3, 6 and 12 months (all p < 0.001);
nonetheless, PRP did not significantly increased the risk of post-injection adverse events (RR, 1.40 [95% CI,
0.80 to 2.45], I2 = 59%, p = 0.24).
Conclusions: Intra-articular PRP injections probably are more efficacious in the treatment of knee OA in terms of pain
relief and self-reported function improvement at 3, 6 and 12 months follow-up, compared with other injections, including
saline placebo, HA, ozone, and corticosteroids.
Review registration: PROSPERO CRD42016045410. Registered 8 August 2016.
Keywords: Platelet-rich plasma, Hyaluronic acid, Knee, Osteoarthritis, Systematic review
* Correspondence: xuetaoxie@163.com
†Equal contributors
1Department of Orthopaedic Surgery, Shanghai Sixth People’s Hospital
affiliated to Shanghai Jiaotong University School of Medicine, 600 Yishan
Road, Shanghai 200233, China
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Shen et al. Journal of Orthopaedic Surgery and Research  (2017) 12:16 
DOI 10.1186/s13018-017-0521-3
Background
Osteoarthritis (OA) is a major cause of knee disability
involving cartilage damage related to an inadequate
healing response in the inflammatory milieu [1]. Current
non-surgical treatment modalities include physiotherapy,
analgesia, non-steroidal anti-inflammatory drugs, and
intra-articular injections, such as hyaluronic acid (HA),
corticosteroids, or Ozone, with the purpose of reducing
symptoms and improving joint function [2–4].
In the past decade, there has been an increasing inter-
est in the use of autologous growth factors, such as
intra-articular injections of platelet-rich plasma (PRP)
for treatment of knee OA [5]. PRP is a fraction of whole
blood and prepared by the centrifugation of autologous
blood, thereby yielding a higher concentration of plate-
lets than baseline values. The regenerative effect and
anti-inflammatory potential of PRP in the tissue healing
process have led to extensive investigation of PRP as a
potential treatment for a variety of musculoskeletal
indications, including OA [6–8].
A number of randomized controlled trials (RCTs)
were reported with favourable outcomes of PRP injec-
tions [9–17]; several reviews, including systematic re-
views and meta-analysis, have been published with
conclusion that PRP was found to be an effective and
safe orthobiologic in the treatment of knee OA com-
pared with other intra-articular injections [18–28].
However, these reviewers also concluded that more
RCTs, in particular high-quality studies, were still
needed. Considering that prior reviews either included
non-RCTs or only synthesized a small number of RCTs
(less than 9) for analysis [18–28] and that quite a few
more RCTs recently have been published [29–35], we be-
lieve that it is necessary to perform an updated systematic
review and meta-analysis, if appropriate, to evaluate
whether the evidence-based support for PRP treatment
will be strengthened or compromised. Furthermore, a
large number of studies may allow us to fully investigate
the temporal effect of PRP specifically on knee pain and
physical function.
Methods
This systematic review was registered online in PROS-
PERO (registration number: CRD42016045410) and was
performed following the guidelines of the PRISMA
statement. The protocol and the PRISMA checklist were
provided as Additional files 1 and 2, respectively.
Inclusion and exclusion criteria
All published RCTs evaluating the efficacy and/or safety
of PRP (or preparations including autologous platelet
concentrate, autologous conditioned plasma, and plasma
rich in growth factors) in the treatment of knee OA in
human were eligible for inclusion. Only studies that
included patients aged 18 years or older with symptom-
atic knee OA and had a minimum follow-up of 12 weeks
were included. All studies had to include at least 1 con-
trol group treated by intra-articular agents other than
PRP. The studies that PRP was used in combination with
operations were excluded. Published abstracts of RCTs
without complete data for analysis were also excluded.
Primary and secondary outcomes
For data synthesis across studies, the primary outcome was
the Western Ontario and McMaster Universities Arthritis
Index (WOMAC) [36]. Specifically, the WOMAC pain
subscores, physical function subscores, and total scores at
3, 6, and 12 months after treatment were recorded. The
secondary outcome was the number of patients reporting
adverse events.
Search strategy
Two investigators performed a systematic search of
Pubmed, Embase, Cochrane library, and Scopus independ-
ently on July 15, 2016 and updated on November 15,
2016. The search strategy was as follows: (platelet[text
word] OR plasma[text word]) AND (knee[text word] OR
tibiofemoral[text word] OR patellofemoral[text word])
AND (*arthritis[text word] OR *arthritic[text word] OR
cartilage[text word] OR *arthrosis[text word] OR gonar-
throsis[text word]) AND random*[text word]. In Scopus,
the search field [text word] was replaced with [TITLE-
ABS-KEY]. No language or date exclusions were applied
(Additional file 3).
Two investigators reviewed all titles and abstracts to
remove duplicates and evaluate the relevance according
to the inclusion and exclusion criteria. If ambiguity was
encountered, the full-text review was performed. Any
discrepancy was resolved through panel discussion with
a third investigator. The references of prior systematic
reviews were also reviewed to find potential eligible
studies.
Data extraction
Two reviewers independently performed data extraction
using a pre-developed data extraction table. We ex-
tracted the basal characteristics of the included studies
to form descriptive summaries. In multi-arm trials
including more than one PRP treatment groups, only
the group treated with at least twice PRP injections was
considered as the intervention group, as the regimen of
multiple PRP injections was more common and reported
to be more efficacious than a single injection [37, 38].
Although data concerning the patients treated with
single-PRP injection in those trials were also extracted,
they were not used for quantitative synthesis. The ex-
tracted data were checked for consistency, and discrep-
ancies were discussed until a consensus was reached.
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Personal correspondence was attempted to obtain
missing data or clarify ambiguous information.
Quality assessment
Two investigators independently assessed the methodo-
logical quality of each eligible study using Review Man-
ager 5.3 (The Cochrane Collaboration, Oxford, England)
to determine the risk of bias. The following domains
were assessed: random sequence generation (selection
bias), allocation concealment (selection bias), blinding of
participants (performance bias), blinding of personnel
(performance bias), blinding of outcome assessment (de-
tection bias), incomplete outcome data (attrition bias),
selective reporting (reporting bias), and other bias. The
risk of bias for each domain was graded as either low
(+), high (−), or unclear (?) [39]. A trial was regarded as
low risk of bias only when all domains were scored as
low risk of bias; if 1 or 2 domains were scored as high or
moderate risk of bias, the trial was regarded as moderate
risk of bias; if more than 2 domains were scored as high
or moderate risk of bias, then high risk of bias was con-
sidered [21]. Differences were settled by panel discussion
with a third investigator.
Data analysis
For the continuous variables, the mean difference (MD)
with 95% confidence interval (CI) was used, while the
relative risk (RR) with 95% CI was adopted for dichot-
omous variables to express intervention effects. We as-
sumed the presence of heterogeneity a priori and used
the random-effects model in all pooled analysis. The I2
was used to test heterogeneity. As defined previously, a
value less than 40% means the heterogeneity might not
be important, whereas the value more than 75% means
considerable heterogeneity [39]. To detect the effect of
individual studies on the pooled effect, sensitivity ana-
lysis was conducted. Publication bias was assessed with a
funnel plot if there were at least 10 studies in a compari-
son [39]. Any p value less than 0.05 was considered to
be statistically significant. All analysis was undertaken
using Review Manager 5.3.
Results
Study characteristics
In total, 14 RCTs [9–11, 13–15, 17, 29–35] were in-
cluded in the analysis published between 2011 and 2016.
Details of the literature search were shown in a flow-
chart (Fig. 1). Search strategy and study selection process
could be found in the Additional file 3.
A total of 1423 patients were included for randomization
(Table 1). The sample size of PRP group ranged from 12 to
96 patients, whereas that of control groups including HA,
placebo, ozone, and corticosteroids, ranged from 11 to 96
participants. WOMAC was the most commonly used
Fig. 1 Study flow diagram
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efficacy outcome, and 9 studies reported WOMAC (8
studies) [9–11, 14, 15, 29, 34, 35] or normalized WOMAC
(1 study) [13] scores. Follow-up intervals and length were
variable among studies. The shortest follow-up was
12 weeks [32] and the longest was 12 months [15, 17, 29,
33, 34]. A summary of PRP intervention effect per study
demonstrated comparable efficacy between PRP and HA
among 215 patients in 2 studies [17, 32] and superior
results in PRP-treated patients compared with control
among 1208 patients in the rest 12 studies [9–11, 13–15,
29–31, 33–35].
PRP treatment protocols varied among studies in
terms of preparation devices, centrifugations, the use of
exogenous activators, and the injection regimen of dose,
times, and intervals (Table 2).
Among the 14 studies, 2 different radiographic OA
grading systems were used: the Kellgren Lawrence
grading (0–IV) [40] in 12 studies [9, 10, 14, 15, 17,
29–35] and the Ahlbäck scale (I–V) [41] in 2 studies
[11, 13] (Table 3). According to the distribution of
these cases, most participants receiving PRP treatment
were at the early or mid-stage of knee OA.
Risk of bias assessment
A summary of risk of bias assessment of all included
studies was illustrated in Fig. 2. Four studies [13, 17, 32,
34] achieved a moderate risk of bias, while the rest 10
[9–11, 14, 15, 29–31, 33, 35] obtained a high risk of bias
(Table 1). A detailed justification of the evaluation of
each domain of bias was described and provided in the
Additional file 4.
Knee pain
At 3 months, 3 studies reported WOMAC pain sub-
scores, and a statistically significant difference was
found in favor of PRP treatment compared with con-
trol (MD, −3.69 [95% CI, −6.87 to −0.51], I2 = 94%,
p = 0.02). At 6 months, the synthesis of 5 studies
demonstrated a statistically significant difference in
favor of PRP treatment (MD, −3.82 [95% CI, −6.40
to −1.25], I2 = 96%, p = 0.004). At 12 months, the
pooling results of 4 studies still favored PRP treat-
ment (MD, −3.76 [95% CI, −5.36 to −2.16], I2 = 86%,
p < 0.001) (Fig. 3).
Table 2 Details of PRP treatment protocols and control
PRP Control
Studies Categorya Preparation Spinning Activation Injection dose, times,
and intervals
Fresh/ frozen Type Injection dose, times,
and intervals
Cerza et al.[9] LP-PRP ACP Single NR 5.5 mL, 4 times, weekly Fresh Hyalgan, 20 mg, 4 times, weekly
Duymus et al.[29] LR-PRP Ycellbio kit Single No 5 mL, 2 times, monthly Fresh Ostensil Plus,
Ozone gas
40 mg, 1 time;
15 mL, 4 times, weekly
Filardo et al.[17] LR-PRP Custom Double CaCl2 5 mL, 3 times, weekly Frozen Hyalubrix, 30 mg, 3 times, weekly
Forogh et al.[30] LR-PRPb TUBEX kit Double CaCl2 5 mL, 1 time Fresh Depo Medrol 40 mg, 1 time




30 mg, 3 times, weekly;
NR, 3 times, weekly
Li et al.[10] LR-PRP Weigao kit Double CaCl2 3.5 mL, 3 times, 3 weeks Fresh Sofast 2 mL, 3 times, 3 weeks
Montañez-Heredia
et al.[35]
LP-PRP Custom Double NR NR, 3 times, 15 days Frozen Adant NR, 3 times, 15 days
Patel et al.[11]c LP-PRP Custom Single CaCl2 8 mL, 2 times, 3 weeks Fresh Saline 8 mL, 1 time
Paterson et al.[32] LR-PRP Custom Double Ultraviolet 3 mL, 3 times, weekly Fresh Hylan G-F 20 3 mL, 3 times, weekly
Raeissadat
et al.[33]
LR-PRP Rooyagen kit Double No 4-6 mL, 2 times, 4 weeks Fresh Hyalgan 20 mg, 3 times, weekly
Sánchez et al.[13] LP-PRP PRGF-Endoret Single CaCl2 8 mL, 3 times, weekly Fresh Euflexxa NR, 3 times, weekly
Smith et al.[34] LP-PRP ACP Single NR 3-8 mL, 3 times, weekly Fresh Saline 3-8 mL, 3 times, weekly
Spaková et al.[14] LR-PRP Custom Triple No 3 mL, 3 times, weekly Fresh Erectus NR, 3 times, weekly
Vaquerizo
et al.[15]
LP-PRP PRGF-Endoret Single CaCl2 8 mL, 3 times, weekly Fresh Durolane NR, 1 time
ACP autologous conditioned plasma, NR not reported, CaCl2 calcium chloride, Depo Medrol methylprednisolone acetate injectable suspension, PRGF plasma rich in
growth factors
aPRP was categorized into two types: LP-PRP (leukocyte-poor PRP) with the level of leukocytes below baseline and LR-PRP (leukocyte-rich PRP) with the level of
leukocytes above baseline [45]
bInformation was obtained from the authors through personal correspondence
cIn a multi-arm trial, the group injected PRP more than once was regarded as an intervention group, and the data about the single-PRP injection group was
not extracted
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Physical function
At 3 months, 3 studies reported WOMAC physical func-
tion subscores, and a statistically significant difference
was found in favor of PRP treatment compared with
control (MD, −14.24 [95% CI, −23.43 to −5.05], I2 = 91%,
p = 0.002). PRP treatment was also found to improve
physical function significantly according to the pooling
analysis of 5 studies at 6 months (MD, −13.51 [95% CI,
−23.77 to −3.26], I2 = 97%, p = 0.01) and 4 studies at
12 months (MD, −13.96 [95% CI, −18.64 to −9.28], I2 =
84%, p < 0.001) (Fig. 4).
Total WOMAC scores
At 3 months, 6 studies reported total WOMAC scores
and a statistically significant difference was found in
favor of PRP treatment compared with control (MD,
−14.53 [95% CI, −21.97 to −7.09], I2 = 90%, p < 0.001).
PRP treatment was also found to improve total
WOMAC scores significantly according to the pooling
analysis of 8 studies at 6 months (MD, −18.21 [95% CI,
−27.84 to −8.59], I2 = 97%, p < 0.001) and 4 studies at
12 months (MD, −19.45 [95% CI, −26.09 to −12.82], I2 =
85%, p < 0.001) (Fig. 5).




0 I II III IV I II III
Cerza et al.[9] PRP 21 24 15
HA 25 22 13
Duymus et al.[29] PRP 22 11
HA 24 10
Ozone 23 12
Filardo et al.[17] PRP 0–IV, Mean ± SD:
2.0 ± 1.1
HA 0–IV, Mean ± SD:
2.0 ± 1.1
Forogh et al.[30]a PRP 7 17
CS 8 16







Placebo I–III, 27 13
Li et al.[10] PRP 6 2 4 3
HA 6 3 3 3
Montañez-Heredia et
al.[35]
PRP 5 10 12
HA 2 9 15








Placebo 25 18 3




Raeissadat et al.[33] PRP 5 34 29 9
HA 0 29 23 10
Sánchez et al.[13] PRP 45 32 12
HA 42 32 11
Smith et al.[34] PRP 8 7
Placebo 10 5
Spaková et al.[14] PRP 2 39 19
HA 2 37 21
Vaquerizo et al.[15] PRP 14 26 8
HA 18 21 9
SD standard deviation, PRP/S single-PRP injection followed by saline injections,
PRP1 single-PRP injection, PRP2 twice PRP injections
aThe number of knees rather than patients was reported
Fig. 2 Risk of bias summary of all included studies. Methodological
quality assessment of each study at 8 domains was illustrated. +
means low risk of bias, ? means unclear risk of bias, and − means
high risk of bias
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Adverse events
A total of 10 studies [9–11, 13–15, 17, 32, 34, 35] re-
corded adverse events. Excluding the study by Filardo et
al. [17], which reported adverse events in a different
form, there was no statistically significant difference in
the number of patients with adverse events between PRP
and HA among the rest 9 studies (RR, 1.40 [95% CI,
0.80 to 2.45], I2 = 59%, p = 0.24) (Fig. 6). All adverse
events were non-specific, the symptoms including pain,
stiffness, syncope, dizziness, headache, nausea, gastritis,
sweating, and tachycardia. No severe complications were
recorded and all the events were self-resolved in days.
Discussion
This systematic review included 14 RCTs and assessed
the temporal effect of PRP on knee pain and physical
function in the treatment of knee OA compared with
other intra-articular injections, including saline, HA,
ozone, and corticosteroids. Data synthesis consistently
showed intra-articular PRP injections significantly
reduced knee pain, improved physical function, and total
WOMAC scores compared with control. Such superiority
was observed at 3, 6, and 12 months after treatment.
However, the risk of adverse events in PRP-treated partici-
pants was not significantly increased in comparison with
other intra-articular injections.
Although previous systematic reviews concluded that
PRP was an effective and safe alternative to treat knee
OA, such conclusion was reached on the basis of less
than 9 RCTs [18–28], and thus the temporal effect of
PRP injections on knee pain and physical function was
not fully investigated. Chang et al. calculated the effect
size of PRP treatment from different outcome measure-
ments at 2, 6, and 12 follow-up, but half of the 16 studies
included for analysis were case series, and 5 were RCTs
[19]. Another systematic review pooled 6 RCTs and found
that PRP obtained significantly better WOMAC total
scores than HA from 3 to 12 months post-injection, how-
ever, only 2 studies reported WOMAC scores at 3 months
and another 2 at 12 months [22]. Laudy et al. specifically
evaluated the effect of PRP injections on knee pain and
physical function at 6 and 12 months post-treatment [21].
Nonetheless, most comparisons included only 1 or 2
studies due to the small number of RCTs pooled for
Fig. 3 Forest plots investigating the effect of PRP on WOMAC pain subscores at 3, 6 and 12 months compared with control. (IV, inverse variance;
M-H, Mantel-Haenszel; CI, confidence interval)
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analysis. Another review included 9 RCTs and synthesized
the WOMAC pain subscores and physical function sub-
scores to compare the efficacy of PRP with control [23].
Due to the varied follow-up among studies, synthesis of
the data at the latest follow-up might not reflect the
changes of PRP efficacy. The strength of this study was to
assess the effect of PRP treatment on knee pain and phys-
ical function at different time-points post-injection based
on a larger number of RCTs.
It remains unclear regarding the duration period of
the beneficial effect of PRP injections. Our study
found that PRP was superior to other intra-articular
injections in terms of pain relief and function im-
provement through 3 to 12 months. Filardo et al. in-
vestigated the persistence of the favorable effect of
PRP infiltration during a 24-month follow-up [42].
Results show that all the evaluated parameters were
significantly reduced at 24 months compared with
those at 12 months, but still better than the baseline
before treatment. The median duration of the clinical
improvement was 9 months. This may explain why all
current RCTs followed participants within 12 months.
The short-term efficacy of PRP injections indicates
that PRP only temporarily influences the joint milieu,
without affecting the joint structure or progression of
knee OA.
There are a few limitations in this review. The placebo
effect was reportedly substantial in the treatment of knee
OA, especially in terms of pain relief and self-reported
function improvement [43]. Interventions that are re-
cently “hot” or that were administered through needles,
such as intra-articular injections, would result in larger
placebo effect [44]. Therefore, blinding of participants is
critical to minimize the potential placebo effect. Half of
the 14 RCTs in this review were believed to have
successfully performed blinding of participants [13,
17, 29–35] according to the risk of bias assessment.
While 2 more studies [11, 15] stated blinding of par-
ticipants, the difference in injection times between
the intervention and control groups actually made it
difficult to perform blinding reliably. So future RCTs
should be designed as double-blinding, which ought
to be performed successfully during the whole trials.
Another limitation is the high heterogeneity among
studies, which was also common in previous reviews
[18–28].
Fig. 4 Forest plots investigating the effect of PRP on WOMAC physical function subscores at 3, 6, and 12 months compared with control. (IV, inverse
variance; M-H, Mantel-Haenszel; CI, confidence interval)
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Fig. 5 Forest plots investigating the effect of PRP on total WOMAC scores at 3, 6, and 12 months compared with control. (IV, inverse variance;
M-H, Mantel-Haenszel; CI, confidence interval)
Fig. 6 Forest plots comparing the risk of adverse events between PRP and control. (M-H, Mantel-Haenszel; CI, confidence interval)
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Conclusions
Intra-articular PRP injections probably are more effica-
cious in the treatment of knee OA in terms of pain relief
and self-reported function improvement at 3, 6, and
12 months follow-up, compared with other injections,
including saline placebo, HA, ozone, and corticosteroids.
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